Mark A Rubin

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. pmc The role of SPINK1 in ETS rearrangement-negative prostate cancers
    Scott A Tomlins
    Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Cancer Cell 13:519-28. 2008
  2. pmc Expression profiling of human renal carcinomas with functional taxonomic analysis
    Michael A Gieseg
    Pfizer Global Research and Development, 2800 Plymouth Rd, Ann Arbor, Michigan 48105, USA
    BMC Bioinformatics 3:26. 2002
  3. ncbi Tissue microarray sampling strategy for prostate cancer biomarker analysis
    Mark A Rubin
    Department of Pathology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0054, USA
    Am J Surg Pathol 26:312-9. 2002
  4. ncbi Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer
    M A Rubin
    Department of Pathology, Urology, and the Comprehensive Cancer and Geriatrics Center of the University of Michigan, Ann Arbor, MI 48109, USA
    J Pathol 195:80-6. 2001
  5. ncbi Tech.Sight. Understanding disease cell by cell
    Mark A Rubin
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Science 296:1329-30. 2002
  6. ncbi alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer
    Mark A Rubin
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
    JAMA 287:1662-70. 2002
  7. ncbi Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy?
    M A Rubin
    Department of Pathology of the University of Michigan, Ann Arbor 48109 0054, USA
    Am J Surg Pathol 24:1634-40. 2000
  8. ncbi Rapid ("warm") autopsy study for procurement of metastatic prostate cancer
    M A Rubin
    Department of Pathology, University of Michigan, Ann Arbor 48109, USA
    Clin Cancer Res 6:1038-45. 2000
  9. pmc Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer
    Bharathi Laxman
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Neoplasia 8:885-8. 2006
  10. pmc Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer
    Rohit Mehra
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer Res 68:3584-90. 2008

Collaborators

Detail Information

Publications114 found, 100 shown here

  1. pmc The role of SPINK1 in ETS rearrangement-negative prostate cancers
    Scott A Tomlins
    Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Cancer Cell 13:519-28. 2008
    ..We identified the aggressive 22RV1 cell line as a SPINK1 outlier expression model and demonstrate that SPINK1 knockdown in 22RV1 attenuates invasion, suggesting a functional role in ETS rearrangement-negative prostate cancers...
  2. pmc Expression profiling of human renal carcinomas with functional taxonomic analysis
    Michael A Gieseg
    Pfizer Global Research and Development, 2800 Plymouth Rd, Ann Arbor, Michigan 48105, USA
    BMC Bioinformatics 3:26. 2002
    ..Nucleic acid array-based technologies extend molecular characterization of tumors to thousands of gene products. To effectively discriminate between tumor sub-types, reliable laboratory techniques and analytic methods are required...
  3. ncbi Tissue microarray sampling strategy for prostate cancer biomarker analysis
    Mark A Rubin
    Department of Pathology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0054, USA
    Am J Surg Pathol 26:312-9. 2002
    ..Conversely, more than 4 cores will not add significant information. This prostate cancer outcomes array should be useful in evaluating other putative prostate cancer biomarkers...
  4. ncbi Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer
    M A Rubin
    Department of Pathology, Urology, and the Comprehensive Cancer and Geriatrics Center of the University of Michigan, Ann Arbor, MI 48109, USA
    J Pathol 195:80-6. 2001
    ..This review will concentrate on the application of laser capture microdissection, cDNA microarrays, and tissue microarrays in the area of prostate cancer research...
  5. ncbi Tech.Sight. Understanding disease cell by cell
    Mark A Rubin
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Science 296:1329-30. 2002
  6. ncbi alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer
    Mark A Rubin
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
    JAMA 287:1662-70. 2002
    ..Molecular profiling of prostate cancer has led to the identification of candidate biomarkers and regulatory genes. Discoveries from these genome-scale approaches may have applicability in the analysis of diagnostic prostate specimens...
  7. ncbi Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy?
    M A Rubin
    Department of Pathology of the University of Michigan, Ann Arbor 48109 0054, USA
    Am J Surg Pathol 24:1634-40. 2000
    ..To properly convey this uncertainty to clinicians, a cautionary note should accompany Gleason scores derived from a minimal focus of carcinoma...
  8. ncbi Rapid ("warm") autopsy study for procurement of metastatic prostate cancer
    M A Rubin
    Department of Pathology, University of Michigan, Ann Arbor 48109, USA
    Clin Cancer Res 6:1038-45. 2000
    ..The development and expansion of this program represent a valuable resource for molecular and clinical researchers...
  9. pmc Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer
    Bharathi Laxman
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Neoplasia 8:885-8. 2006
    ..These results demonstrate that TMPRSS2:ERG gene fusions can be detected in the urine of patients with prostate cancer and support larger studies on prospective cohorts for noninvasive detection of prostate cancer...
  10. pmc Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer
    Rohit Mehra
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer Res 68:3584-90. 2008
    ..These findings suggest that TMPRSS2-ERG with Edel is an aggressive and, in this study, uniformly lethal molecular subtype of prostate cancer associated with androgen-independent disease...
  11. pmc Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer
    Sooryanarayana Varambally
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Neoplasia 10:1285-94. 2008
    ..0009) versus 0.495 for serum PSA (P = .902). Our data indicating the up-regulation of GOLM1 expression and its appearance in patients' urine suggest GOLM1 as a potential novel biomarker for clinically localized prostate cancer...
  12. pmc Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States
    Juan Miguel Mosquera
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 15:4706-11. 2009
    ..We sought to determine the prevalence of TMPRSS2-ERG gene fusion among prostate-specific antigen-screened men undergoing prostate biopsy in the United States...
  13. ncbi Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 0602, USA
    Science 310:644-8. 2005
    ..These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer...
  14. ncbi Prognostic factors in lymph node-positive prostate cancer
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Urology 67:1016-21. 2006
    ..The incidence of clinically localized PCa with concurrent lymph node metastasis has decreased to less than 1% in the United States but is between 10% and 15% in other countries...
  15. ncbi Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations
    Rajal B Shah
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor 48109, USA
    Am J Clin Pathol 122:517-23. 2004
    ..The cocktail provides a simple, cost-effective improvement in basal cell immunohistochemical analysis of difficult prostate lesions...
  16. pmc Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer
    Sunita R Setlur
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    J Natl Cancer Inst 100:815-25. 2008
    ....
  17. pmc ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease
    Rainer Kuefer
    Department of Urology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109 0944, USA
    Neoplasia 8:319-29. 2006
    ..These results suggest that ADAM15 is generally overexpressed in adenocarcinoma and is highly associated with metastatic progression of prostate and breast cancers...
  18. pmc Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model
    Kirsten D Mertz
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115 6110, USA
    Neoplasia 9:200-6. 2007
    ..The androgen receptor-negative NCI-H660 cell line expresses ERG in an androgen-independent fashion. This in vitro model system has the potential to provide important pathobiologic insights into TMPRSS2-ERG fusion prostate cancer...
  19. ncbi Integrative analysis of genomic aberrations associated with prostate cancer progression
    Jung H Kim
    Michigan Center for Translational Pathology, Department of Pathology, Department of Urology, Program of Bioinformatics, and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109 0940, USA
    Cancer Res 67:8229-39. 2007
    ..Integrative analysis with matched mRNA profiles identified genetic alterations in several proposed candidate genes implicated in prostate cancer progression...
  20. ncbi Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer
    Daniel R Rhodes
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA
    J Natl Cancer Inst 95:661-8. 2003
    ....
  21. pmc Role of the TMPRSS2-ERG gene fusion in prostate cancer
    Scott A Tomlins
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Neoplasia 10:177-88. 2008
    ..Our results support previous work suggesting that TMPRSS2-ERG fusions mediate invasion, consistent with the defining histologic distinction between PIN and prostate cancer...
  22. ncbi Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells
    Ming Zhou
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA
    Am J Surg Pathol 27:365-71. 2003
    ..We recommend this basal cell cocktail for routine Pca diagnostic work-up...
  23. ncbi Autoantibody signatures in prostate cancer
    Xiaoju Wang
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    N Engl J Med 353:1224-35. 2005
    ..New biomarkers, such as autoantibody signatures, may improve the early detection of prostate cancer...
  24. ncbi Integrative molecular concept modeling of prostate cancer progression
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nat Genet 39:41-51. 2007
    ..Taken together, these data show that analyzing gene expression signatures in the context of a compendium of molecular concepts is useful in understanding cancer biology...
  25. ncbi Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis
    Agnieszka K Witkiewicz
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Epidemiol Biomarkers Prev 14:1418-23. 2005
    ..Quantitative image analysis is a novel way to accurately and reproducibly evaluate immunohistochemistry in breast tissue samples using high-density tissue microarrays...
  26. ncbi Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer
    Arun Sreekumar
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
    J Natl Cancer Inst 96:834-43. 2004
    ..However, attempts to detect AMACR in circulation have not been successful. Hence, we determined whether an immune response to AMACR could be used as a serum biomarker for prostate cancer...
  27. pmc Defining aggressive prostate cancer using a 12-gene model
    Tarek A Bismar
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Neoplasia 8:59-68. 2006
    ..0015). This study demonstrates that cross-platform models can lead to predictive models with the possible advantage of being more robust through this selection process...
  28. pmc Internet-based Profiler system as integrative framework to support translational research
    Robert Kim
    Department of Pathology, Brigham and Women s Hospital, Boston, USA
    BMC Bioinformatics 6:304. 2005
    ..The Profiler system allows investigator to reliably track, store, and evaluate TMA experiments. Here within we describe the process that has evolved through an empirical basis over the past 5 years at two academic institutions...
  29. ncbi The polycomb group protein EZH2 is involved in progression of prostate cancer
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 419:624-9. 2002
    ..Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression...
  30. ncbi Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
    Scott A Tomlins
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 448:595-9. 2007
    ..Furthermore, the identification of androgen-repressed and insensitive 5' fusion partners may have implications for the anti-androgen treatment of advanced prostate cancer...
  31. doi Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer
    Kirsten D Mertz
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Int J Cancer 123:569-76. 2008
    ..Distinct molecular subtypes of ccRCC with prognostic relevance were identified, and the CK7/CK19 expressing subtype is associated with better outcome...
  32. ncbi Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions
    Caleb P Nelson
    Departments of Urology and Pathology, University of Michigan, Ann Arbor, MI, USA
    Urol Oncol 21:213-8. 2003
    ..Tabulated 5-year PSA-free survival outcomes, stratified by these preoperative parameters, provide a basis for preoperative counseling of patients regarding postprostatectomy cancer control expectations...
  33. ncbi The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer
    Rainer Kuefer
    Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0944, USA
    Clin Cancer Res 9:6447-52. 2003
    ..The purpose of this study was to evaluate an 80 kDa proteolytic fragment of E-cadherin as a potential biomarker for prostate cancer progression and to identify putative proteases that are responsible for the cleavage of E-cadherin...
  34. ncbi Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Cell 8:393-406. 2005
    ....
  35. pmc Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications
    Juan Miguel Mosquera
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Clin Cancer Res 14:3380-5. 2008
    ..This may have significant clinical implications given that TMPRSS2-ERG fusion prostate cancer is associated with a more aggressive clinical course...
  36. ncbi TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion
    Sven Perner
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115 6110, USA
    Am J Surg Pathol 31:882-8. 2007
    ..Furthermore, its clinical application as a biomarker and ancillary diagnostic test is promising given its high specificity...
  37. ncbi TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer
    Sven Perner
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, EBRC 442A, 221 Longwood Avenue, Boston, MA 02115 6110, USA
    Cancer Res 66:8337-41. 2006
    ..The deletion as cause of TMPRSS2:ERG fusion is associated with clinical features for prostate cancer progression compared with tumors that lack the TMPRSS2:ERG rearrangement...
  38. ncbi The role of metastasis-associated protein 1 in prostate cancer progression
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cancer Res 64:825-9. 2004
    ..In summary, this study identified an association of MTA1 expression and prostate cancer progression...
  39. ncbi Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer
    Rohit Mehra
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Mod Pathol 20:538-44. 2007
    ....
  40. doi Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, 2Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 69:640-6. 2009
    ....
  41. ncbi Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arch Pathol Lab Med 130:989-96. 2006
    ..The metastasis-associated gene 1 (MTA1) is overexpressed in several human cancers. Recent reports suggest that MTA1 may play a role in cancer progression either through transcription repression and/or hormone receptor interactions...
  42. ncbi Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program
    Rajal B Shah
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Cancer Res 64:9209-16. 2004
    ..An appreciation of this heterogeneity is critical to evaluating diagnostic and prognostic biomarkers as well as to designing therapeutic targets for advanced disease...
  43. ncbi Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer
    Joanne N Davis
    Department of Urology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer Res 66:11897-906. 2006
    ..Taken together, these results show that elevated E2F1, through its ability to repress AR transcription, may contribute to the progression of hormone-independent prostate cancer...
  44. pmc Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Neoplasia 6:503-12. 2004
    ..2-fold downregulation). Taken together, this study suggests that only a small subset of PCas may be amenable to tyrosine kinase inhibitors specific for PDGFR...
  45. pmc Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy
    Mara P Steinkamp
    Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI 48109 5618, USA
    Cancer Res 69:4434-42. 2009
    ..Thus, treatment with antiandrogens selects for gain-of-function AR mutations with altered stability, promoter preference, or ligand specificity. These processes reveal multiple targets for effective therapies regardless of AR mutation...
  46. pmc Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma
    Ritu Bhalla
    Michigan Center for Translational Pathology, Ann Arbor, MI, USA
    Mod Pathol 26:835-48. 2013
    ..Automated dual ERG-PTEN and ERG-SPINK1 immunohistochemisty assays are simple, reliable and portable across study sites for the simultaneous assessment of these proteins in prostate cancer...
  47. ncbi TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109, USA
    Cancer Res 66:3396-400. 2006
    ..This result defines a third molecular subtype of prostate cancer and supports the hypothesis that dysregulation of ETS family members through fusions with TMRPSS2 may be an initiating event in prostate cancer development...
  48. pmc Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer
    Chandan Kumar-Sinha
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0602, USA
    Am J Pathol 164:787-93. 2004
    ..Taken together, our studies suggest that AMACR activity is increased in prostate cancer relative to benign epithelia and suggests that monitoring AMACR activity levels in prostate needle biopsies may have clinical applications...
  49. pmc α-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study
    Marc Barry
    Department of Pathology, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts, USA
    Prostate 72:301-6. 2012
    ..Recent studies suggest that low AMACR expression is associated with biochemical recurrence and the development of fatal disease...
  50. ncbi Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115 6110, USA
    Lab Invest 86:1099-102. 2006
    ..The clinical implications of this discovery are significant for diagnosis and potentially for the development of targeted therapy...
  51. ncbi Identification of two molecular groups of seminomas by using expression and tissue microarrays
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Cancer Res 11:5722-9. 2005
    ..One group of seminomas has a molecular profile similar to embryonal carcinoma. The findings in the current study may help explain aberrant immunoprofiles seen with some seminomas...
  52. ncbi JAGGED1 expression is associated with prostate cancer metastasis and recurrence
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 64:6854-7. 2004
    ....
  53. ncbi Haploinsufficiency and reduced expression of genes localized to the 8p chromosomal region in human prostate tumors
    Hassan Chaib
    Department of Urology, The University of Michigan, Ann Arbor 48109, USA
    Genes Chromosomes Cancer 37:306-13. 2003
    ....
  54. pmc EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
    Celina G Kleer
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:11606-11. 2003
    ..This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation...
  55. ncbi Current thoughts on the role of the androgen receptor and prostate cancer progression
    Sunita R Setlur
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Adv Anat Pathol 12:265-70. 2005
    ..The need for the design of novel therapeutic analogues is also emphasized...
  56. doi Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer
    Sunita R Setlur
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer Epidemiol Biomarkers Prev 19:229-39. 2010
    ..Given PCA's strong genetic component, we evaluated the possibility that variation in genes involved in DHT metabolism influence PCA risk...
  57. pmc Whole transcriptome amplification for gene expression profiling and development of molecular archives
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
    Neoplasia 8:153-62. 2006
    ..Taken together, WTA represents a versatile approach to profile and archive cDNA from minute tumor samples and is compatible with partially degraded RNA...
  58. pmc Dysregulation of the annexin family protein family is associated with prostate cancer progression
    Wei Xin
    Department of Pathology and the Comprehensive Cancer Center, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Am J Pathol 162:255-61. 2003
    ..Finally, down-regulation of several annexin family members may play a role in the development of the lethal PCa phenotype...
  59. ncbi Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer
    Sunita R Setlur
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 67:10296-303. 2007
    ..Our results indicate that this pathway is especially dysregulated in hormone-refractory prostate cancer...
  60. pmc Characterization of KRAS rearrangements in metastatic prostate cancer
    Xiao Song Wang
    Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer Discov 1:35-43. 2011
    ..This is the first report of a gene fusion involving the Ras family, suggesting that this aberration may drive metastatic progression in a rare subset of prostate cancers...
  61. ncbi Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer Res 64:3814-22. 2004
    ..In summary, these findings suggest that dysregulation of TPD52 by genomic amplification and androgen induction may play a role in prostate cancer progression...
  62. ncbi A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines
    Christopher H Chay
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0946, USA
    Urology 60:760-5. 2002
    ..To identify genes important in prostate cancer metastatic to bone. Bone-specific metastasis is a common feature of prostate cancer and a significant cause of morbidity...
  63. ncbi Using molecular markers to predict outcome
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Urol 172:S18-21; discussion S21-2. 2004
    ..Developing molecular tests to predict prostate cancer progression requires first defining meaningful clinical end points and defining strategies to take advantage of emerging technology...
  64. ncbi Integrative biology of prostate cancer progression
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Annu Rev Pathol 1:243-71. 2006
    ..This review addresses candidate genes involved in prostate cancer pathogenesis in a biological and clinical context and demonstrates how integrated analysis of high-throughput data augments our understanding of prostate cancer...
  65. ncbi Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty
    Saravana Mohan Dhanasekaran
    Department of Pathology, University of Michigan Medical School, Ann Arbor 48109 0602, USA
    FASEB J 19:243-5. 2005
    ....
  66. ncbi Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer
    Kirsten D Mertz
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 38:1454-62. 2007
    ..MVA determination by AQUA is an objective and reliable method to quantify tumor vascularization in ccRCC. A large MVA correlates with a high MVD and is associated with better patient prognosis...
  67. ncbi Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens
    Tara Jane Browne
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 35:1462-8. 2004
    ..However, a limitation of this approach is the loss of tissue in these small lesions, suggesting that combining AMACR and the BCC on a single slide would be superior to using either marker separately...
  68. pmc Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens
    Atreya Dash
    Department of Urology, University of Michigan, Ann Arbor, USA
    Am J Pathol 161:1743-8. 2002
    ....
  69. ncbi Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy
    Caleb P Nelson
    Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Urology 59:740-5; discussion 745-6. 2002
    ..Information relating preoperative parameters to recurrence-free survival is needed to counsel patients with newly diagnosed prostate cancer regarding expectations for postprostatectomy cancer control...
  70. ncbi Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions
    Ming Zhou
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, USA
    Am J Surg Pathol 26:926-31. 2002
    ..In conclusion, our study suggests that AMACR is potentially an important tumor marker for several cancers and their precursor lesions, especially those linked to high-fat diets...
  71. ncbi Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer
    Atreya Dash
    Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Urology 60:276-80. 2002
    ..We therefore compared the recurrence risk in cases with bladder neck involvement with that of cases with extraprostatic extension and/or seminal vesicle invasion...
  72. doi ETS gene fusions in prostate cancer: from discovery to daily clinical practice
    Scott A Tomlins
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA
    Eur Urol 56:275-86. 2009
    ..In 2005, fusions between the androgen-regulated transmembrane protease serine 2 gene, TMPRSS2, and E twenty-six (ETS) transcription factors were discovered in prostate cancer...
  73. ncbi Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations
    Lakshmi P Kunju
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA
    Am J Clin Pathol 120:737-45. 2003
    ..Most HGPINs show diffuse moderate P504S staining. AAH may show focal P504S staining. We recommend using P504S along with morphologic examination and conventional basal cell markers...
  74. pmc Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements
    Mark A Rubin
    Department of Pathology, Brigham and Women s Hospital, and the Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Pathol 164:831-40. 2004
    ..In the future, the AMACR AQUA Z-score may be useful in the automated screening and evaluation of prostate tissue biomarkers...
  75. ncbi Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma
    Cecelia E Schmalbach
    Department of Otolaryngology Head and Neck Surgery, University of Michigan Medical School, Ann Arbor 48109 0656, USA
    Arch Otolaryngol Head Neck Surg 130:295-302. 2004
    ..To investigate differences in gene expression profiles between oral cavity/oropharynx squamous cell carcinoma (OC/OP SCC) primary tumors that have metastasized to cervical lymph nodes and nonmetastatic OC/OP SCC tumors...
  76. ncbi Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer
    Rajal B Shah
    Deparment of Pathology and Urology, University of Michigan School of Medicine and Comprenhensive Cancer Center, Ann Arbor, Michigan 48109, USA
    Am J Surg Pathol 26:1161-8. 2002
    ..p63 may be used as an alternative to 34betaE12 stain for difficult prostate lesions...
  77. ncbi Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity
    Willie Underwood
    Department of Urology, University of Michigan, Ann Arbor, MI, USA
    Urol Oncol 22:20-4. 2004
    ..Studies are needed to evaluate the possible interaction of prostate cancer stage and grade shift in African American men and the disease free survival in this population...
  78. pmc alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation
    Rainer Kuefer
    Department of Pathology, University of Michigan Medical School, Ann Arbor 48109 0602, USA
    Am J Pathol 161:841-8. 2002
    ..Taken together, these data suggest that AMACR expression is not hormone-dependent but may in fact be a marker of tumor differentiation...
  79. pmc Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival
    Dinesh S Rao
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    J Clin Invest 110:351-60. 2002
    ..HIP1 represents a putative prognostic factor for prostate cancer and a potential therapy target in prostate as well as colon cancers...
  80. ncbi PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism
    Kwanchanit Tantivejkul
    Department of Urology, The Michigan Urology Center, University of Michigan, Ann Arbor, Michigan 48109, USA
    J Cell Biochem 96:641-52. 2005
    ....
  81. pmc Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability
    Celina G Kleer
    Department of Pathology, Division of Hematology and Oncology, 2G332 University Hospital, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0054, USA
    Am J Pathol 160:579-84. 2002
    ..RhoC is specifically expressed in invasive breast carcinomas capable of metastasizing, and it may be clinically useful in patients with tumors smaller than 1 cm to guide treatment...
  82. ncbi Differential expression of cytokeratins 8 and 20 distinguishes craniopharyngioma from rathke cleft cyst
    Wei Xin
    Department of Pathology and the Comprehensive Cancer Center, University of Michigan Medical Center, Ann Arbor 48109, USA
    Arch Pathol Lab Med 126:1174-8. 2002
    ..Distinguishing craniopharyngioma from Rathke cleft cyst is sometimes difficult, and the distinction is clinically significant because Rathke cleft cysts have a better prognosis than craniopharyngiomas...
  83. ncbi Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Mod Pathol 22:933-9. 2009
    ..This may suggest a potential role for metastasis-associated gene 1 in the malignant progression and metastasis and its use as biomarker for malignant pancreatic endocrine tumors...
  84. pmc Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis
    H Chaib
    Department of Surgery, Section of Urology, The University of Michigan, Ann Arbor, MI 48109 0946, USA
    Neoplasia 3:43-52. 2001
    ....
  85. pmc Loss of expression of human spectrin src homology domain binding protein 1 is associated with 10p loss in human prostatic adenocarcinoma
    J A Macoska
    Department of Surgery, The University of Michigan School of Medicine, Ann Arbor, MI 48109-0946, USA
    Neoplasia 3:99-104. 2001
    ..These data are consistent with a role for Hssh3bp1 as a candidate tumor suppressor gene inactivated during prostate tumorigenesis...
  86. ncbi Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy
    M Zhou
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    J Urol 166:2193-7. 2001
    ..Nuclear morphology is subject to tissue fixation and processing artifact. Any nuclear morphometric study must consider this artifact...
  87. ncbi E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology
    M A Rubin
    Departments of Pathology, Surgery-Urology Section, University of Michigan, Ann Arbor, MI 48109-0054, USA
    Hum Pathol 32:690-7. 2001
    ..Metastatic prostate cancer shows strong E-cadherin expression as determined by anti-E-cadherin antibody HECD-1...
  88. ncbi Morphological features of TMPRSS2-ERG gene fusion prostate cancer
    J M Mosquera
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115 6110, USA
    J Pathol 212:91-101. 2007
    ..These features may also be helpful in diagnosing TMPRSS2-ERG fusion prostate cancer, which may have both prognostic and therapeutic implications...
  89. ncbi Prevalence and location of peripheral nerve found on prostate needle biopsy
    M Zhou
    Department of Pathology, University of Michigan, Ann Arbor, USA
    Am J Clin Pathol 115:39-43. 2001
    ..Careful examination of routine H&E-stained specimens is sufficient to detect all important PNI...
  90. ncbi Delineation of prognostic biomarkers in prostate cancer
    S M Dhanasekaran
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 412:822-6. 2001
    ..Thus, the integration of cDNA microarray, high-density tissue microarray, and linked clinical and pathology data is a powerful approach to molecular profiling of human cancer...
  91. pmc Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model
    S Manley
    Department of Pathology, University of Michigan Comprehensive Cancer and Geriatrics Center, Ann Arbor, Michigan 48109-0946, USA
    Am J Pathol 159:837-43. 2001
    ..Because the review is performed over the Internet, this system is ideal for collaborative multi-institutional studies...
  92. pmc Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander?
    R Shah
    Department of Pathology, Section of Urology, University of Michigan, Ann Arbor, Michigan, USA
    Am J Pathol 158:1767-73. 2001
    ..Gain of 8c is significantly greater in PAH than benign prostate, SA, and even HGPIN. These findings demonstrate a strong association between PAH and PCA, supporting its role as a neoplastic precursor...
  93. ncbi Analysis of three-dimensional Doppler ultrasonographic quantitative measures for the discrimination of prostate cancer
    A P Moskalik
    Department of Basic Radiological Sciences, University of Michigan, Ann Arbor 48109-0553, USA
    J Ultrasound Med 20:713-22. 2001
    ..CONCLUSION: Doppler ultrasonography does provide discriminatory information for prostate cancer, with color pixel density being the most promising measure...
  94. ncbi Web-based tissue microarray image data analysis: initial validation testing through prostate cancer Gleason grading
    G S Bova
    Department of Pathology, Johns Hopkins University, Baltimore, MD 21287-6417, USA
    Hum Pathol 32:417-27. 2001
    ..hum pathol 32:417-427...
  95. ncbi Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: incidence and clinical implications
    M A Rubin
    Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Am J Surg Pathol 22:840-8. 1998
    ..The close association between high tumor volume and HGCP supports the theory that the development of HGCP is a late event in tumor progression, more compatible with the intraductal spread of tumor than dysplasia...
  96. ncbi Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate
    M G Rashid
    Department of Surgery, and the University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor 48109-0944, USA
    Cancer Res 61:489-92. 2001
    ..Herein, we report the first experiment comparing case-matched human normal and cancerous prostate tissue in the context of E-cadherin truncation...
  97. ncbi Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer
    Y Q Wu
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109-0946, USA
    Cancer Res 61:8651-3. 2001
    ..Taken together, inactivation of the HPC2/ELAC2 gene via LOH is a relatively uncommon event in prostate cancer. Future studies will determine whether 17p LOH occurs in the subset of patients with an inherited mutation in HPC2/ELAC2...
  98. ncbi Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer
    S J Kielb
    Departments of Urology and Pathology, Prostate Cancer and Urological Oncology Program, University of Michigan, Ann Arbor, Michigan, USA
    J Urol 166:482-7. 2001
    ..These findings provide a rationale for selecting chemotherapy based on the p53 status of individual bladder cancers...
  99. ncbi TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
    F Demichelis
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115 6110, USA
    Oncogene 26:4596-9. 2007
    ..005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression...
  100. ncbi Analysis of three-dimensional ultrasound Doppler for the detection of prostate cancer
    A Moskalik
    Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Urology 57:1128-32. 2001
    ..These results also objectively verify previous visual studies suggesting a modest improvement with the use of color Doppler...
  101. ncbi Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death
    Mark A Rubin
    Department of Pathology Amory 3 195, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:1424-32. 2005
    ..This is the first study to show that AMACR expression is significantly associated with prostate cancer progression and suggests that not all surrogate end points may be optimal to define biomarkers of aggressive prostate cancer...